- Academic Editor
†These authors contributed equally.
Background: Atrial septal defect (ASD) patients commonly experience
severe pulmonary arterial hypertension (SPAH), which is frequently associated
with a poor prognosis. While serum bilirubin levels, indicative of liver
function, are known predictors of right heart failure (RHF), their potential to
differentiate SPAH in ASD patients is yet to be ascertained. The purpose of this
study was to discover the potential correlations between serum bilirubin levels
and ASD patients with SPAH. Methods: In this cross-sectional
study, 102 ASD patients admitted from December 2019 to November 2020
were enrolled and divided into two cohorts: those with SPAH and those without.
Blood tests were conducted to measure serum direct bilirubin (DBIL), total
bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase
(AST), uric acid (UA) and N-terminal pro B-type natriuretic peptide (NT-proBNP).
Additionally, all participants underwent transthoracic echocardiography, and
invasive hemodynamic data were gathered through right heart catheterization.
Results: ASD patients with SPAH exhibited significantly elevated serum
DBIL (5.2
Atrial septal defect (ASD) is a frequently occurring congenital heart deficit. Between 6% and 35% of ASD patients develop pulmonary arterial hypertension (PAH), which can lead to increased mortality, diminished cardiac function, and atrial tachyarrhythmias [1, 2, 3, 4, 5, 6]. Severe pulmonary arterial hypertension (SPAH) in patients with ASD has a poor prognosis [7]. Currently, therapeutic strategies for ASD with SPAH are controversial. Our previous study demonstrated that mean pulmonary arterial pressure (mPAP) was a simple but powerful predictor of the benefits of ASD closure in these patients, with an optimal cut-off value of 35 mmHg and an area under the curve (AUC) of 0.919 [5].
Nevertheless, in ASD patients with SPAH, closure may not always decrease pulmonary artery pressure due to factors like vessel remodeling and decreased vascular compliance in ASD patients with SPAH [6]. Yong et al. [8] reported that after transcatheter ASD closure, most patients with severe PAH continue to have elevated pulmonary artery pressures, which might be due to irreversible vessel changes [7]. Therefore, it is important to identify SPAH in ASD patients to choose the best timing for ASD occlusion. While right heart catheterization has long been the gold standard for determining SPAH, the procedure is invasive. There is a growing emphasis on biomarker studies to prompt an earlier initiation of more aggressive therapies. These biomarkers may be used for identifying potential SPAH in ASD patients.
Bilirubin is a promising biomarker for assessing patients within this population. It is a metabolic byproduct of hemoglobin breakdown that also acts as an endogenous antioxidant molecule [9]. Total bilirubin (TBIL) is well established prognostic factor in heart failure [10] and PAH [8]. However, most prior PAH studies focused on patients with predominantly idiopathic or connective tissue disease-related cases. Few studies have focused solely on ASD-associated PAH, which has distinct pulmonary hemodynamics and pathophysiology. Since the role of bilirubin in ASD-SPAH remains unknown, this study was undertaken to investigate the role of serum bilirubin to assess its significance in ASD patients, especially in those with SPAH.
This cross-sectional study included 102 patients with ASD admitted to Zhongshan
Hospital, Fudan University, from December 2019 to November 2022. The diagnosis of
PAH was based on right-heart catheterization values [11]: mPAP
Baseline characters and clinical data were collected from electronic medical records. TTE was performed using Vivid 7GE (G.E. Healthcare, Chicago, IL, USA) by an experienced sonographer, and echocardiographic parameters including left ventricular ejection fraction (LVEF), left atrial diameter (LAD), and left ventricular end-diastolic (LVED) were validated by two cardiology consultants. The diameter, type, and size of the defect and the anatomy of the ASD were examined by cardiology consultants. This study was performed in compliance with the Helsinki Declaration and was approved by the Ethics Committee. Written informed consent was obtained from all participants.
The peripheral venous blood samples were obtained with the consent of the patients. Serum TBIL, direct bilirubin (DBIL), uric acid (UA), aspartate transaminase (ASL), alanine transaminase (ALT), and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured just before right heart catheterization at the Central Clinical Laboratory of our Hospital. The normal value of TBIL is 1.71–17.1 µmol/L, and DBIL 1.71–7.0 µmol/L in our lab.
Right heart catheterization was employed by cardiologists to evaluate PAH severity. A multipurpose catheter was inserted into the right atrium via the inferior vena cava and placed in the pulmonary veins across the ASD. A Swan-Ganz balloon-tipped catheter was placed in the pulmonary arteries through the right atrium and right ventricle. Hemodynamic parameters such as pulmonary arterial systolic pressure (PASP) and mPAP were then evaluated.
Continuous variables with a normal distribution were presented as mean
In total, 102 patients were included in the study, 28 were in the ASD with SPAH
cohort and 74 were in ASD without SPAH cohort. Their baseline characters,
clinical, biochemical, hemodynamic, and echocardiographic data are presented in
Table 1. There were no statistically significant differences in terms of mean
age, sex, LAD, and LVEF between the two cohorts. However, the ASD with SPAH
cohort had a significantly larger defect size (26.0
Variables | ASD without SPAH | ASD with SPAH | p values | |
n = 74 | n = 28 | |||
Age, years | 42.4 |
45.5 |
0.38 | |
Male (%) | 25 (33.8%) | 6 (21.4%) | 0.23 | |
TTE and RHC | ||||
ASD diameter, mm | 16.4 |
26.0 |
||
PASP, mmHg | 33.0 |
83.9 |
||
mPAP, mmHg | 24.3 |
50.4 |
||
PADP, mmHg | 9.1 |
23.6 |
||
TAPSE, mm | 19.6 |
14.9 |
||
LVEF, % | 65.4 |
64.8 |
0.45 | |
LAD, mm | 37.1 |
38.6 |
0.25 | |
LVED, mm | 43.5 |
37.8 |
||
RVD, mm | 33.1 |
49.3 |
||
TR |
11 (14.9%) | 15 (53.6%) | ||
Blood Examination | ||||
DBIL, µmol/L | 2.4 |
5.2 |
||
TBIL, µmol/L | 10.1 |
24.6 |
||
DBIL/TBIL | 0.2 |
0.3 |
0.52 | |
ALT, U/L | 20.7 |
18.1 |
0.37 | |
AST, U/L | 19.5 |
20.6 |
0.51 | |
UA, µmol/L | 317.8 |
403.5 |
||
NT-proBNP, pg/mL | 52 (33.3, 119.3) | 525 (129.3, 626) |
Data are presented as mean
Abbreviation: ASD, atrial septal defect; SPAH, severe pulmonary arterial
hypertension; TTE, transthoracic echocardiography; RHC, right heart
catheterization; PASP, pulmonary arterial systolic pressure; PADP, pulmonary
arterial diastolic pressure; mPAP, mean pulmonary arterial pressure; TAPSE,
tricuspid annular plane systolic excursion; LVEF, left ventricular ejection
fraction; LAD, left atrial diameter; LVED, left ventricular end diastolic; RVD,
right ventricle diameter; TR, tricuspid regurgitation; DBIL, direct bilirubin;
TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; UA, uric acid; NT-proBNP, N-terminal pro B-type natriuretic
peptide. Note: p
Table 1 indicates that ASD patients with SPAH had significantly higher serum
levels of DBIL (5.2
Serum biomarkers levels in ASD patients with or without SPAH.
(A–F) demonstrated the serum DBIL, TBIL, NT-proBNP, UA, ALT, and
AST level in ASD patients with and without SPAH groups respectively (*** means
p
Using the Pearson correlation, relationships between variables were analyzed. These variables include baseline characters (age, male), biochemical and hemodynamic variables (DBIL, TBIL, DBIL/TBIL, NT-proBNP, UA, AST and ALT), echocardiographic parameters (ASD diameter, RVD, LVEF, LAD, TAPSE) and right heart catheterization (pulmonary artery systolic pressure [sPAP], mPAP). Serum DBIL levels had a positive correlation with multiple cardiac ultrasound, right heart catheterisation, and blood biochemistry indicators. While serum TBIL showed positive correlations with some factors (ASD diameter, RVD, sPAP, mPAP, DBIL, UA, and NT-proBNP), there were negative correlations with others (LVED, TAPSE, and DBIL/TBIL ratio). Serum NT-proBNP also had many significant correlations (age, ASD diameter, RVD, LAD, LVED, TAPSE, sPAP, mPAP, TBIL, DBIL, and UA). Finally, serum UA was also correlated with various factors (ASD diameter, LVEF, LAD, sPAP, mPAP, TBIL, DBIL/TBIL ratio, and NT-proBNP). More detailed statistics, including r values and levels of significance can be found in Table 2 and Fig. 2.
Variables | DBIL | TBIL | NT-proBNP | UA | ||||
r | p | r | p | r | p | r | p | |
Age | –0.010 | 0.924 | 0.030 | 0.763 | 0.241 | 0.015 | 0.162 | 0.103 |
Male | 0.054 | 0.102 | –0.061 | 0.544 | –0.127 | 0.203 | 0.124 | 0.215 |
ASD diameter | 0.198 | 0.047 | 0.341 | 0.531 | 0.354 | |||
RVD | 0.340 | 0.208 | 0.036 | 0.410 | 0.145 | 0.102 | ||
LVEF | –0.020 | 0.840 | –0.103 | 0.192 | –0.103 | 0.303 | –0.210 | 0.034 |
LAD | 0.053 | 0.594 | 0.083 | 0.408 | 0.226 | 0.022 | 0.195 | 0.050 |
LVED | –0.273 | –0.483 | –0.435 | 0.006 | 0.952 | |||
TAPSE | –0.264 | 0.007 | –0.357 | –0.383 | 0.004 | 0.102 | ||
sPAP | 0.325 | 0.296 | 0.003 | 0.494 | 0.467 | |||
mPAP | 0.523 | 0.499 | 0.470 | 0.799 | ||||
TBIL | 0.683 | - | - | 0.418 | 0.236 | 0.017 | ||
DBIL | - | - | 0.683 | 0.437 | 0.085 | 0.397 | ||
DBIL/TBIL | 0.329 | –0.207 | 0.037 | 0.038 | 0.703 | –0.267 | 0.007 | |
UA | 0.085 | 0.397 | 0.236 | 0.017 | 0.197 | 0.047 | - | - |
AST | –0.016 | 0.492 | –0.016 | 0.878 | 0.129 | 0.200 | 0.045 | 0.658 |
ALT | –0.080 | 0.428 | –0.088 | 0.382 | –0.060 | 0.551 | 0.167 | 0.100 |
NT-proBNP | 0.437 | 0.418 | - | - | 0.197 | 0.047 |
Abbreviation: ASD, atrial septal defect; RVD, right ventricle diameter; mPAP,
mean pulmonary arterial pressure; LVEF, left ventricular ejection fraction; LAD,
left atrial diameter; LVED, left ventricular end diastolic; DBIL, direct
bilirubin; TBIL, total bilirubin; UA, uric acid; NT-proBNP, N-terminal pro B-type
natriuretic peptide; TAPSE, tricuspid annular plane systolic excursion; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; sPAP, pulmonary artery
systolic pressure. Note: p
Correlations of serum biomarkers with various parameters. Abbreviation: ASD, atrial septal defect; RVD, right ventricle diameter; mPAP, mean pulmonary arterial pressure; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVED, left ventricular end diastolic; DBIL, direct bilirubin; TBIL, total bilirubin; UA, uric acid; NT-proBNP, N-terminal pro B-type natriuretic peptide; TAPSE, tricuspid annular plane systolic excursion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SPAP, pulmonary artery systolic pressure.
To explore the association between various parameters and PASP in ASD patients,
linear regression analyses were performed (Table 3). Single-variable linear
regression showed that ASD diameter, TBIL, DBIL, RVD, TAPSE, NT-proBNP and UA
were significantly associated with increased mPAP among ASD patients with SPAH.
Further multivariate linear regression analysis demonstrated that serum DBIL
(
Variable | Single-variable | Multi-variable | ||
p | p | |||
ASD diameter | 0.679 | 0.125 | 0.358 | |
RVD | 0.775 | 0.370 | 0.001 | |
TAPSE | –2.503 | –1.083 | 0.003 | |
TBIL | 0.016 | 0.106 | 0.343 | |
DBIL | 3.258 | 1.552 | 0.015 | |
DBIL/TBIL | –3.278 | 0.796 | - | - |
ALT | –0.152 | 0.192 | - | - |
AST | 0.027 | 0.902 | - | - |
NT-proBNP | 0.021 | 0.001 | 0.690 | |
UA | 0.059 | 0.030 | 0.007 |
Abbreviation: mPAP, mean pulmonary arterial pressure; ASD, atrial septal defect; TAPSE, tricuspid annular plane systolic
excursion; RVD, right ventricle diameter; DBIL, direct bilirubin; TBIL, total
bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; UA,
uric acid; NT-proBNP, N-terminal pro B-type natriuretic peptide. Note: p
Table 3, Fig. 3 and Supplementary Table 2 outline distinct
discriminative values. A DBIL level of 2.15 mg/dL is effective in distinguishing
ASD with SPAH patients from those without SPAH, achieving a sensitivity of 92.9%
and a specificity of 51.4% (AUC: 0.794, 95% confidence interval [CI]:
0.701–0.886, p
ROC analyses of serum biomarkers predicting ASD patients with SPAH. Abbreviation: ROC, receiver operating characteristic; ASD, atrial septal defect; SPAH, severe pulmonary artery hypertension; DBIL, direct bilirubin; TBIL, total bilirubin; UA, uric acid; NT-proBNP, N-terminal pro B-type natriuretic peptide.
This study demonstrates that elevated bilirubin levels (both DBIL and TBIL) are present in patients with both ASD and SPAH. Both DBIL and TBIL levels correlated with the cardiac function markers NT-proBNP, RVD, TAPSE, LVED, PASP and mPAP. Moreover, DBIL alone or in combination with UA can differentiate between ASD patients with SPAH and without SPAH with relatively high sensitivity and specificity.
Our study showed serum TBIL and DBIL were increased in ASD patients with SPAH, but without any concurrent increase in AST or ALT. The mechanisms causing elevated serum levels of TBIL and DBIL in ASD patients with SPAH are still unclear. One hypothesis suggests that for ASD patients, the elevated mPAP may increase the right atrial and ventricular load, which is expected to increase the risk of right heart failure (RHF). This RHF condition could manifest as liver dysfunction, potentially due to hepatic stasis and reduced perfusion. Changes in the right heart hemodynamic may be due to elevated central venous pressure (CVP) via the hepatic vein into the small hepatic veins [13]. This impairment can further hinder the delivery of oxygen and nutrients to hepatocytes, resulting in the expansion of sinusoidal fenestrations [13]. The resulting cholestatic and hypoxic hepatic injury caused by elevated CVP may contribute to an increase of bilirubin. In fact, DBIL has been identified as a critical marker of elevated CVP in other studies [10, 14, 15]. Furthermore, other researchers have highlighted the positive correlation between serum bilirubin with right atrial pressure and the severity of tricuspid regurgitation [16]. In our study, the damage to hepatocytes was limited, as indicated by the absence of statistical differences in ALT and AST between ASD with or without the SPAH. However, the liver biomarkers DBIL and TBIL were reflective of right heart function and were associated with the risk of SPAH in ASD patients.
Some basic researchers have sought to explore the relationship between bilirubin
and PAH. Bilirubin is a tetrapyrrole pigment in blood that has both direct and
indirect forms, and is known for its antioxidant and anti-inflammatory activity
[17, 18, 19]. Physiological concentrations of bilirubin inhibit nuclear factor kappa-B
(NF-
Our study demonstrated that the serum DBIL and TBIL levels can predict SPAH in ASD patients, with DBIL demonstrating a sensitivity of 92.9% and a specificity of 51.4%, while TBIL exhibited a sensitivity of 89.3% and a specificity of 62.2%. Echoing our observations, Xu et al. [26] showed that abnormally elevated DBIL was independently linked to all-cause mortality among idiopathic PAH patients, and treating PAH survivors significantly decreased serum DBIL levels. In contrast, almost no decrease in serum DBIL was found in non-survivors [27]. In addition, hyper-bilirubinemia (TBIL) was associated with advanced RHF, which then markedly reduced survival in patients with PAH [24]. Gong et al. [28] found that elevated serum bilirubin and reduced six-minute walk distance (6MWD) was identified as a predictor of adverse outcomes in patients with chronic thromboembolic pulmonary hypertension. While our study did not evaluate the prognostic implications for ASD patients with abnormal DBIL and TBIL levels, we observed that patients with SPAH presented more severe structural and hemodynamic symptoms compared to their non-SPAH counterparts. Therefore, our future research will focus on defining the role of DBIL and TBIL in predicting the prognosis of ASD patients with SPAH.
We observed that ASD patients with SPAH had significantly higher UA levels when compared to those without SPAH. Supporting this, Yan et al. [29] found that baseline hyperuricemia and high variability in serum UA were associated with higher 5-year mortality in patients with idiopathic PAH (IPAH). Savale et al. [30] suggests that UA levels can partly reflect the severity of PAH, with higher concentrations of UA promoting mild proliferation of pulmonary artery smooth muscle cells in patients with idiopathic PAH and in rat models. In our studies, DBIL levels combined with UA had a sensitivity (92.9%) and specificity (71.6%) to discriminated ASD individuals with SPAH. Therefore, UA combined with DBIL might better predict poor prognosis in these patients.
Our study has several limitations. Firstly, 6MWD was not analyzed in regression analysis due to incomplete data, preventing us from supplementing the study with 6MWD results. Secondly, the organizational roles of DBIL and TBIL in ASD patients with SPAH have not been explored in our study. Attempts to solve this problem using both animal and cellular experiments are underway. Thirdly, long-term follow-up should be conducted to evaluate whether DBIL and TBIL could predict the prognosis of ASD patients suffering from SPAH. In conclusion, given our current sample size, it’s challenging to rule out potential discrepancies. Further extensive, large-scale studies are needed to validate our findings.
Overall, we found that elevated serum DBIL and TBIL levels in ASD patients with SPAH are correlated with prognostic clinical markers. Utilizing DBIL combined with UA may serve as a safe, cost-effective, and powerful predictor of SPAH in patients with ASD, potentially introducing a novel therapeutic biomarker.
The datasets generated and/or analyzed during the current study are not publicly available due to local rules national laws but are available from the corresponding author on reasonable request.
WZP and DXZ designed the research study. FZ, QJ, and DWL performed the research. DDC and LHG provided help and advice on design and manuscript formation. DWL and JNF analyzed the data. FZ, DWL, QJ and JNF wrote the manuscript. WZP and DXZ reviewed the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
This study was conducted according to the principles stated in the Declaration of Helsinki. Ethics approval for the study was granted by the Ethics Committees of Zhongshan Hospital, Fudan University (B2022-593R), and all subjects provided written informed consent.
We would like to acknowledge the contribution of the staff at the 38th ward, cardiac catheter laboratory, and echocardiography units at Zhongshan Hospital.
This work was supported by Shanghai Clinical Research Center Project for Interventional Medicine (19MC1910300) and Youth research project of Jinshan Hospital, Fudan University (JYQN-JC-202010).
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.